Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide
0.1.0 - ci-build
Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
| Official URL: https://nshr-uat.sha.go.ke/fhir/ValueSet/nccp-ocm-protocol-markers-vs | Version: 0.1.0 | ||||
| Active as of 2026-06-04 | Computable Name: OCMProtocolMarkersVS | ||||
Biomarker and molecular marker codes for treatment protocol selection.
References
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs version 📦0.1.0
Expansion performed internally based on codesystem Kenya OCM Protocol Markers Code System v0.1.0 (CodeSystem)
This value set contains 17 concepts
| System | Code | Display (en) | Definition | JSON | XML |
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | HER2-POSITIVE | HER2 Positive | HER2/neu overexpression or amplification detected. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | HER2-NEGATIVE | HER2 Negative | No HER2/neu overexpression or amplification. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | ER-POSITIVE | ER Positive | Oestrogen receptor positive. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | ER-NEGATIVE | ER Negative | Oestrogen receptor negative. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | PR-POSITIVE | PR Positive | Progesterone receptor positive. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | PR-NEGATIVE | PR Negative | Progesterone receptor negative. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | TRIPLE-NEGATIVE | Triple Negative | ER-, PR-, HER2- breast cancer. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | KRAS-MUTANT | KRAS Mutant | KRAS mutation detected. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | KRAS-WILD-TYPE | KRAS Wild-type | No KRAS mutation. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | BRAF-V600E | BRAF V600E Mutant | BRAF V600E mutation detected. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | PD-L1-POSITIVE | PD-L1 Positive | PD-L1 expression ≥1%. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | PD-L1-NEGATIVE | PD-L1 Negative | PD-L1 expression <1%. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | MSI-HIGH | MSI-High | Microsatellite instability high. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | MSI-LOW | MSI-Low / MSS | Microsatellite instability low or stable. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | EGFR-MUTANT | EGFR Mutant | EGFR mutation detected. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | ALK-POSITIVE | ALK Positive | ALK rearrangement detected. | ||
https://nshr-uat.sha.go.ke/fhir/CodeSystem/ocm-protocol-markers-cs | NOT-TESTED | Not Tested | Biomarker testing not performed. |